All In Biotech

Drug Trial Radar · NCT06660290

A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes

A Phase 3b Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes

Last checked: Nov 20, 2026Latest source record: Mar 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

55

Actual

Start

Jan 15, 2025

Primary completion

Feb 6, 2025

Study completion Feb 6, 2025

Sponsor

Lead sponsor
Alcon ResearchIndustry
Sponsor type
Industry
First posted
Oct 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the percentage of ocular adverse events reported in subjects with dry eye disease (DED) between the intervention arm (0.003% AR-15512) and control arm (REFRESH® Classic).

Conditions

  • Dry Eye Disease

Interventions

  • 0.003% AR-15512 ophthalmic solutionDrug

    Investigational ophthalmic solution administered topically in 4 different instillation variations: 512-RT (0.003% AR-15512 instilled at room temperature, eyes to remain open post-drop instillation); 512-COLD (0.003% AR-15512 stored in refrigerator and instilled immediately after removal from refrigerator, eyes to remain open post-drop instillation); 512-RT-EC (0.003% AR-15512 instilled at room temperature followed by subjects immediately closing their eyes); and 512-COLD-EC (0.003% AR-15512 stored in refrigerator and instilled immediately after removal from refrigerator followed by subjects immediately closing their eyes).

  • Artificial tearsDrug

    Commercially available, preservative-free lubricant eye drops administered topically

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects With Ocular Treatment-Emergent Adverse Events Attributed to Study InterventionTime frame: Up to Day 1 post drop instillation

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Eye Research Foundation

    Newport Beach, California

  • Vision Institute

    Colorado Springs, Colorado

  • Andover Eye Associates

    Andover, Massachusetts

  • Total Eye Care, PA

    Memphis, Tennessee

  • Advancing Vision Research, LLC

    Smyrna, Tennessee

  • Piedmont Eye Center

    Lynchburg, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.